Abstract: The invention relates to methods and compositions for treatment of IL13R?2-overexpressing cancer, wherein the treatment comprises administering a protein tyrosine phosphatase-1B (PTP1B) inhibitor.

Abstract: The invention relates to a peptide comprising the amino acid sequence SEQ ID NO: 1 or a variant thereof capable of inhibiting IL13/IL13R?2 signalling. The invention also relates to a fusion protein, nanoparticle, virus-like particle and pharmaceutical composition comprising said peptide, and to their use for treating a cancer characterized by having increased expression of IL13R?2, or for treating asthma, atopic dermatitis or fibrosis, or for preventing the metastatic progression of a cancer characterized by having increased expression of IL13R?2.

Abstract: The invention relates to methods and compositions for treatment of IL13R?2-overexpressing cancer, wherein the treatment comprises administering a protein tyrosine phosphatase-1B (PTP1B) inhibitor.

Abstract: The invention relates to a peptide comprising the amino acid sequence SEQ ID NO: 1 or a variant thereof capable of inhibiting IL13/IL13R?2 signalling. The invention also relates to a fusion protein, nanoparticle, virus-like particle and pharmaceutical composition comprising said peptide, and to their use for treating a cancer characterized by having increased expression of IL13R?2, or for treating asthma, atopic dermatitis or fibrosis, or for preventing the metastatic progression of a cancer characterized by having increased expression of IL13R?2.

Abstract: The disclosure relates to agents binding specifically to human cadherin 17 (CDH17), and/or to human cadherin 5 (CDH5), and/or to human cadherin 6 (CDH6), and/or to human cadherin 20 (CDH20). The disclosure also relates to the use of these agents in therapy, methods for diagnosis and/or prognosis and/or stratification of a cancer in a subject, and pharmaceutical compositions comprising said agents. The disclosure also relates to cancer markers and markers of metastasis.

Abstract: The disclosure relates to agents binding specifically to human cadherin 17 (CDH17), and/or to human cadherin 5 (CDH5), and/or to human cadherin 6 (CDH6), and/or to human cadherin 20 (CDH2O). The disclosure also relates to the use of these agents in therapy, methods for diagnosis and/or prognosis and/or stratification of a cancer in a subject, and pharmaceutical compositions comprising said agents. The disclosure also relates to cancer markers and markers of metastasis.

Abstract: The present invention relates to a method for obtaining useful data for the diagnosis, prognosis or monitoring of colorectal cancer (CRC) progression, to a method for the diagnosis of CRC, to a method for the prognosis of CRC and to a kit for carrying out said methods.

Abstract: Autoantibodies to different proteins useful as biomarkers for the diagnosis, prognosis or monitoring of the progress of a colorectal cancer (CRC) are described.

Abstract: The IBDV VP2 icosahedral superstructures are made up of 12 empty VP2 dodecahedral capsids, lacking genetic material. They have a size of approximately 60–68 nm in diameter and contain 720 IBDV VP2 subunits. These VP2 icosahedral superstructures can be used for vaccinal and diagnostic purposes.

Abstract: The recombinant fusion proteins comprise the protein of the nucleocapsid of the porcine reproductive and respiratory syndrome virus (PRRSV) obtained both from a European isolate of PRRSV as well as from an American isolate, fused to a sequence of amino acids derived from the system chosen for the expression of said recombinant fusion protein, either directly or by means of a binding area formed by a small number of amino acids. These recombinant fusion proteins are suited for their use in the diagnosis of PRRSV.

Abstract: The recombinant fusion proteins comprise the protein of the nucleocapsid of the porcine reproductive and respiratory syndrome virus (PRRSV) obtained both from a European isolate of PRRSV as well as from an American isolate, fused to a sequence of amino acids derived from the system chosen for the expression of said recombinant fusion protein, either directly or by means of a binding area formed by a small number of amino acids. These recombinant fusion proteins are suited for their use in the diagnosis of PRRSV.

Abstract: The recombinant fusion proteins comprise the protein of the nucleocapsid of the porcine reproductive and respiratory syndrome virus (PRRSV), obtained both from a European isolate of PRRSV as well as from an American isolates, fused to a sequence of amino acids derived from the system chosen for the expression of said recombinant fusion protein, either directly or by means of a binding area formed by a small number of amino acids. These recombinant fusion proteins are suited for their use in the diagnosis of PRRSV.

Abstract: Recombinant proteins of the causative virus of porcine reproductive and respiratory syndrome (PRRS), corresponding to ORFs 2 to 7 of the PRRSV Spanish isolate (PRRS-Olot), have been produced in baculovirus expression system using Sf9 cell cultures as a permissive host. These recombinant proteins are suitable for the formulation of vaccines capable of efficaciously protecting porcine livestock from PRRS and for the preparation of diagnostic kits adequate for detection of anti-PRRSV antibodies as well as of PRRSV in a pig biological sample. This invention is of interest to Veterinary Medicine.

Abstract: The present invention is a method for the production of a subunit vaccine against canine parvovirus (CPV). The method includes the step wherein a recombinant protein VP2 of CPV is obtained by using the replication of a recombinant baculovirus wherein the gene corresponding to VP2 has been previously inserted in cells of a permissive host. The protein VP2 obtained has the capacity of forming empty VP2 capsids with high immunogenicity and can be provided as a vaccine formulation for protecting dogs against CPV infection the recombinant baculovirus AcMNPV.pCPVEx17 expresses the VP2 of CPV in conditions making possible the formulation of pseudo-viral capsids.

Abstract: An immunogenic peptide for use in the prevention of parvovirus infections having a contiguous sequence of 6 to 25 amino acids. The peptide is produced from autonomous parvoviruses so as to be capable of inducing neutralizing antibodies against such viruses. These peptides correspond to antigenic sites located in the first 25 amino acids of the amino terminal end of the VP2 proteins of parvoviruses. When these peptides are coupled to carrier proteins or to other immunogenic complexes, they can be used in the formulation of vaccines appropriate to protect dogs, cats, pigs and minks against the infections caused by the parvoviruses.